top of page
  • Recruiting

NCT03732703: Phase 1/2: Myeloma-Developing Regimens Using Genomics (MyDRUG)

Updated: Sep 27, 2022

Multiple Myeloma Research Consortium




NCT03732703: Phase 1/2: Myeloma-Developing Regimens Using Genomics (MyDRUG)

Multiple Myeloma Research Consortium



The MyDRUG study is a type of Precision Medicine trial to treat patients with drugs targeted to affect specific genes that are mutated as part of the disease. Mutations in genes can lead to uncontrolled cell growth and cancer. Patients with a greater than 25% mutation to any of the following genes; CDKN2C, FGFR3, KRAS, NRAS, BRAF V600E, IDH2 or T(11;14) can be enrolled to one of the treatment arms. These arms have treatments specifically directed to the mutated genes. Patients that do not have a greater than 25% mutation to the genes listed can be enrolled to a non-actionable treatment arm.

The genetic sequencing of the patient's tumor is required via enrollment to the MMRF002 study: Clinical-grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell Malignancies. (NCT02884102).


Multiple Myeloma Research Consortium



Celgene Corporation

Eli Lilly and Company

Genentech, Inc.

Janssen, LP



Karyopharm Therapeutics Inc

Multiple Locations Identifier: NCT03732703

Official Title: Myeloma-Developing Regimens Using Genomics (MyDRUG) (Genomics Guided Multi-arm Trial of Targeted Agents Alone or in Combination With a Backbone Regimen)

First Posted : November 7, 2018

Click here for details on


Drug: Abemaciclib, dexamethasone, ixazomib, pomalidomide

Drug: Enasidenib, dexamethasone, ixazomib, pomalidomide

Drug: Cobimetinib, dexamethasone, ixazomib, pomalidomide

Drug: Erdafitinib, dexamethasone, ixazomib, pomalidomide

Drug: Venetoclax, dexamethasone, ixazomib, pomalidomide

Drug: Daratumumab, dexamethasone, ixazomib, pomalidomide

Drug: Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide

Drug: Selinexor, dexamethasone, ixazomib, pomalidomide


The Multiple Myeloma Research Consortium® (MMRC®)

What is the MMRC®?

What is the MyDRUG study?

NCT01454297: MMRF CoMMpass Study in Newly Diagnosed Multiple Myeloma - (CoMMpass)

NCT03657251: MMRF CureCloud Research Initiative


- Multiple locations

- Arizona: Mayo Clinic Arizona

- California: City of Hope Duarte

- Georgia: Emory University Atlanta

- Massachusetts: Dana-Farber Cancer Institute/Harvard Cancer Center Boston

- Massachusetts: Massachusetts General Hospital Boston

- Minnesota: Mayo Clinic Rochester Minnesota

- Missouri: Washington University School of Medicine Saint Louis

- New York: Memorial Sloan-Kettering Cancer Center New York

- New York: Tisch Cancer Institute Mount Sinai Hospital New York

- New Jersey: Hackensack University Medical Center

- North Carolina: Levine Cancer Institute Charlotte

- Texas: UT Southwestern Medical Center Dallas



United States, Arizona

United States, California

United States, Georgia

United States, Massachusetts

United States, Michigan

United States, Minnesota

United States, Missouri

United States, New Jersey

United States, New York

United States, North Carolina

United States, Ohio

United States, Texas


Posts Archive
bottom of page